Literature DB >> 17237833

Is long-term glucocorticoid therapy associated with a high prevalence of asymptomatic vertebral fractures?

Robert S Weinstein1.   

Abstract

Entities:  

Year:  2007        PMID： 17237833      PMCID： PMC2040103          DOI： 10.1038/ncpendmet0372

Source DB:  PubMed          Journal:  Nat Clin Pract Endocrinol Metab        ISSN： 1745-8366


× No keyword cloud information.
  5 in total

Review 1.  Glucocorticoid-induced osteoporosis.

Authors:  R S Weinstein
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

2.  Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone.

Authors:  R S Weinstein; R L Jilka; A M Parfitt; S C Manolagas
Journal:  J Clin Invest       Date:  1998-07-15       Impact factor: 14.808

3.  Bone loss in response to long-term glucocorticoid therapy.

Authors:  V LoCascio; E Bonucci; B Imbimbo; P Ballanti; S Adami; S Milani; D Tartarotti; C DellaRocca
Journal:  Bone Miner       Date:  1990-01

4.  Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.

Authors:  T P Van Staa; R F Laan; I P Barton; S Cohen; D M Reid; C Cooper
Journal:  Arthritis Rheum       Date:  2003-11

5.  Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength.

Authors:  Charles A O'Brien; Dan Jia; Lilian I Plotkin; Teresita Bellido; Cara C Powers; Scott A Stewart; Stavros C Manolagas; Robert S Weinstein
Journal:  Endocrinology       Date:  2003-12-22       Impact factor: 4.736
  5 in total
  6 in total

Review 1.  Glucocorticoid-induced osteoporosis and osteonecrosis.

Authors:  Robert S Weinstein
Journal:  Endocrinol Metab Clin North Am       Date:  2012-05-23       Impact factor: 4.741

2.  Glucocorticoid dose determines osteocyte cell fate.

Authors:  Junjing Jia; Wei Yao; Min Guan; Weiwei Dai; Mohammad Shahnazari; Rekha Kar; Lynda Bonewald; Jean X Jiang; Nancy E Lane
Journal:  FASEB J       Date:  2011-06-24       Impact factor: 5.191

3.  Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization.

Authors:  Wei Yao; Zhiqiang Cheng; Aaron Pham; Cheryl Busse; Elizabeth A Zimmermann; Robert O Ritchie; Nancy E Lane
Journal:  Arthritis Rheum       Date:  2008-11

4.  Prevalence of fractures in women with rheumatoid arthritis and/or systemic lupus erythematosus on chronic glucocorticoid therapy.

Authors:  Maria Luz Rentero; Encarna Amigo; Nicolas Chozas; Manuel Fernández Prada; Lucia Silva-Fernández; Miguel Angel Abad Hernandez; Jose Maria Rodriguez Barrera; Javier del Pino-Montes
Journal:  BMC Musculoskelet Disord       Date:  2015-10-15       Impact factor: 2.362

5.  Beyond bone mineral density, FRAX-based tailor-made intervention thresholds for therapeutic decision in subjects on glucocorticoid: A nationwide osteoporosis survey.

Authors:  Shan-Fu Yu; Jia-Feng Chen; Yin-Chou Chen; Han-Ming Lai; Chi-Hua Ko; Wen-Chan Chiu; Fu-Mei Su; Chung-Yuan Hsu; Ben Yu-Jih Su; Chih-Hsing Wu; Tien-Tsai Cheng
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

6.  Comparative effectiveness of bisphosphonate treatments for the prevention of re-fracture in glucocorticoid-induced osteoporosis: protocol for a systematic review and meta-analysis.

Authors:  Hongmin Chu; Bo-Hyoung Jang; GaYoon Kim; Seowoo Bae; Hyeju Lee; Seonghee Nam; Jeonghoon Ahn
Journal:  BMJ Open       Date:  2022-09-26       Impact factor: 3.006
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.